- SportsYahoo Sports
"If they don’t stand for their flag and stand strongly, I’d be very happy if they didn’t open," Trump said of the NFL.
- BusinessUSA TODAY
6 national restaurant chains in deepest trouble amid COVID-19 include Outback Steakhouse, IHOP and Denny's
Will more restaurants close or file for bankruptcy amid COVID-19? Chains like Outback, Applebee's and IHOP are most at risk for not paying back debts.
The supermodel's 17-year-old daughter Lila Grace Moss joined her for a fun day at the beach
- LifestyleGood Morning America
As over 20 million across the globe have been diagnosed with COVID-19, scientists from Duke University took a look at face masks to see which ones work best in slowing the spread of coronavirus. In their study, they looked at 14 masks including N-95s, N-95s with valves and surgical masks to see how effective each was in keeping droplets from getting out. “It was mainly focused on the technique, a simple technique to visualize these droplet emissions and the effects of masks,” said Dr. Martin Fisher, an associate research professor from Duke University.
- U.S.Men's Health
This mask isn't effective, according to the CDC.
- BusinessThe Week
Since the early days of the coronavirus pandemic, the United States has emphasized ratcheting up vaccine production even before federal approval so that, if and when the time comes, the stockpile is ready to go. The same can't be said about a potential treatment known as monoclonal antibodies, however, Stat News reports.Monoclonal antibodies are pretty much what they sound like — antibodies that have been genetically engineered into new medicines. Immunologists and virologists are reportedly optimistic they could play a role in fighting COVID-19, and data from two separate clinical trials run by Regeneron Pharmaceuticals and Eli Lilly are expected to be released in the fall, possibly indicating whether the therapies are safe and effective.But even if they are, it may be too late. Former Food and Drug Administration Commissioner Scott Gottlieb said the U.S. "may have a missed a window" to scale up production of the treatments, which otherwise "could have been an important bridge to a vaccine." Perhaps more importantly, he added, they could also serve as a "hedge in the event vaccines are delayed or don't work." Ultimately, despite the antibodies' potential to change the tides of the pandemic, Gottlieb said, "we just don't have enough doses to realize that goal." Read more at Stat News.More stories from theweek.com Trump has pretty much eliminated daily intelligence briefings. Biden has already started receiving them. The case against American truck bloat Kamala Harris hammers Trump's coronavirus 'failure' in 1st speech as VP candidate
Hertz is selling almost 200,000 cars in bankruptcy, and it doesn't take much money to land in an almost new car.From Autoweek